Drug
marimastat
marimastat is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
20%
Ph phase_1
1
20%
Ph phase_3
3
60%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)
Trials by Status
not_yet_recruiting120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
not_yet_recruitingphase_2
Trial of Oral Community SVMP INhibitors for Snakebite
NCT07500233
completedphase_3
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
NCT00003010
completedphase_3
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
NCT00003011
completedphase_3
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00002911
completedphase_1
Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
NCT00261391
Clinical Trials (5)
Showing 5 of 5 trials
NCT07500233Phase 2
Trial of Oral Community SVMP INhibitors for Snakebite
NCT00003010Phase 3
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
NCT00003011Phase 3
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
NCT00002911Phase 3
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00261391Phase 1
Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5